Morris County Chamber of Commerce
  • JOIN
    • Become a Member
    • Premier Membership
    • What Members Are Saying >
      • Share a Testimonial
    • Membership Inquiry
    • The Value of Membership >
      • Grow Your Business
      • Build Your Brand
      • Professional Development & Education
      • Government Advocacy
      • Community Outreach & Volunteering
    • New Member Survey
    • Power of Connection
  • About
    • Chamber Team
    • Our Mission
    • Our President
    • Board of Directors
    • Morris Business Cabinet
    • President's Circle
    • Chamber Champions
    • Ambassadors Council
    • Inclusivity Advisory Council
    • Frequently Asked Questions
    • Code of Conduct & COVID Policy
  • Membership
    • Member Benefits
    • Forums & Committees >
      • Committee Chair Application
      • Business Development Forum
      • Business Strategy Forum
      • Health & Wellness Forum
      • Not For Profit Roundtable
      • Real Estate Forum
      • RISE Morris: Young Professionals Forum
      • Women in Business Program >
        • WIB Event Committee
    • Member to Member Deals
    • Member Marketing Opportunities
    • Grand Opening Support
    • Conference Room Usage
    • Member Referral Bonus
    • Connect to Morris Job Bank
  • Events
    • Chamber Event Calendar
    • Member Events Calendar
    • Signature Events & Programs
    • Golf Donations 2025
    • Event Photos
    • Submit an Event Idea
    • CCM Grant-Supported Training
  • Directory
    • Searchable Business Directory
    • Nonprofit Giving Guide 2024
    • Member Spotlights
    • Enhance Your Directory Listing
  • News & Info
    • Electronic Certificate of Origin
    • Business Resources & Info
    • Chamber Magazines
    • News Around the Chamber >
      • Around the Chamber Archive
      • Submit a Press Release
    • MCCC Blog >
      • Contribute to Our Blog
    • Members' Bookshelf >
      • Members Library Submission
  • Programs
    • Economic Development Corp
    • EDC Business Counseling
    • Public Policy Series
    • CEO Round Table
    • Lead Morris >
      • Lead Morris Program
      • Lead Morris Alumni Council
      • LEAD Morris Alumni Directory
      • Lead Morris FAQs
      • Lead Morris Application
      • LEAD Morris News & Info
      • Share a LEAD Morris Testimonial
    • Women In Business >
      • Women in Business Mastermind
      • Women in Business Executive Round Table
      • Women in Golf Program
    • Entrepreneur Roundtable
    • Thrive Morris >
      • Thrive Morris Community Leaders
      • Thrive Morris Blog
      • Contribute to the Thrive Morris Blog
  • Member Portal

Around the Chamber

​News & Information from our Members for our Members
​Click Here to submit your Press Release
​Click Here for Past 'Around the Chamber' eNewsletters

Pfizer and BioNTech to Co-Develop Potential COVID-19 Vaccine

3/24/2020

 
Picture
March 17, 2020 | The companies will jointly develop BioNTech’s mRNA-based vaccine candidate BNT162 to prevent COVID-19 infection.  This collaboration aims to accelerate global development of BNT162, by leveraging expertise and resources of both companies.  
NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the companies have agreed to a letter of intent regarding the co-development and distribution (excluding China) of a potential mRNA-based coronavirus vaccine aimed at preventing COVID-19 infection. The companies have executed a Material Transfer and Collaboration Agreement to enable the parties to immediately start working together.
“Management’s Discussion and Analysis of Financial Condition and Results of Operations”
Tweet thisThe collaboration aims to accelerate development of BioNTech’s potential first-in-class COVID-19 mRNA vaccine program, BNT162, which is expected to enter clinical testing by the end of April 2020. The rapid advancement of this collaboration builds on the research and development collaboration into which Pfizer and BioNTech entered in 2018 to develop mRNA-based vaccines for prevention of influenza.
“We are proud that our ongoing, successful relationship with BioNTech gives our companies the resiliency to mobilize our collective resources with extraordinary speed in the face of this worldwide challenge,” said Mikael Dolsten, Chief Scientific Officer and President, Worldwide Research, Development & Medical, Pfizer. “We believe that by pairing Pfizer’s development, regulatory and commercial capabilities with BioNTech’s mRNA vaccine technology and expertise as one of the industry leaders, we are reinforcing our commitment to do everything we can to combat this escalating pandemic, as quickly as possible.”
“This is a global pandemic, which requires a global effort. In joining forces with our partner Pfizer, we believe we can accelerate our effort to bring a COVID-19 vaccine to people around the world who need it,” said Ugur Sahin, Co-Founder and CEO of BioNTech.
The companies expect to utilize multiple research and development sites from both companies, including in the United States and Germany, to house the activities identified by the collaboration agreement.
The companies will begin collaborating immediately. They will finalize details of the agreement regarding financial terms, and all activities related to development, manufacturing and potential commercialization over the next few weeks.
On March 13, 2020, Pfizer issued a five-point plan calling on the biopharmaceutical industry to join the company in committing to unprecedented collaboration to combat COVID-19.
About Pfizer: Breakthroughs That Change Patients’ Lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.
Pfizer Disclosure Notice:
The information contained in this release is as of March 17, 2020. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
This release contains forward-looking information about Pfizer’s efforts to combat COVID-19, BioNTech’s potential COVID-19 mRNA vaccine, BNT162, a letter of intent regarding the co-development and co-commercialization (excluding China) by Pfizer and BioNTech of BNT162 and a Material Transfer and Collaboration Agreement, including their potential benefits, and the expected timing of a Phase 1 trial, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, whether and when a definitive agreement will be reached for the co-development and co-commercialization by Pfizer and BioNTech of BNT162 ; uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from the clinical studies; whether and when any biologics license applications may be filed in any other jurisdictions for BNT162 or any other vaccine candidates under the collaboration; whether and when any such applications may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether BNT162 will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of BNT162; uncertainties regarding the ability to obtain recommendations from vaccine technical committees and other public health authorities regarding BNT162 and uncertainties regarding the commercial impact of any such recommendations; and competitive developments.
A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.
About BioNTech
Biopharmaceutical New Technologies (BioNTech) is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Eli Lilly and Company, Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Genevant, Fosun, and Pfizer.
For more information, please visit www.BioNTech.de.
Forward-looking statement
This press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, the ability of BioNTech to develop and commercialize a vaccine for COVID-19, BioNTech’s potential COVID-19 mRNA vaccine, BNT162, a letter of intent regarding the co-development and co-commercialization (excluding China) by Pfizer and BionNTech of BNT162 and a Material Transfer and Collaboration Agreement, including their potential benefits, and the expected timing of a Phase 1 trial of BNT162. Any forward-looking statements in this press release are based on BioNTech’s current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: competition to create a vaccine for Covid-19 and potential difficulties. For a discussion of these and other risks and uncertainties, see the section entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in BioNTech’s Registration Statement on Form F-1 filed with the SEC on September 9, 2019, as amended, which has been filed with the SEC and is available on the SEC’s website at www.sec.gov. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.


ContactsPfizer:
Media Relations
Amy Rose (U.S.)
+1 (212) 733-7410
[email protected]

Lisa O’Neill (UK)
+44 7929339560
lisa.o'[email protected]

Investor Relations
Ryan Crowe
+1 (212) 733-8160
[email protected]

BioNTech Contacts:
Media Relations
Jasmina Alatovic, Senior Manager Global External Communications
+49 (0)6131 9084 1513 or +49 (0)151 1978 1385
[email protected]

Investor Relations
Sylke Maas, Ph.D., VP Investor Relations & Business Strategy
+49 (0)6131 9084 1074
[email protected]


Comments are closed.

    Archives

    July 2025
    June 2025
    May 2025
    April 2025
    March 2025
    February 2025
    January 2025
    December 2024
    November 2024
    October 2024
    September 2024
    August 2024
    July 2024
    June 2024
    May 2024
    March 2024
    February 2024
    January 2024
    December 2023
    November 2023
    October 2023
    September 2023
    August 2023
    July 2023
    June 2023
    May 2023
    April 2023
    March 2023
    February 2023
    January 2023
    December 2022
    November 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020

    Categories

    All
    Bio Tech
    CARES Act
    Commercial Real Estate
    Coronavirus
    Economic Development
    Education
    Essential Business
    Event
    Giveaway
    Grand Opening
    Grants
    Healthcare
    Health & Wellness
    IT Solutions
    Legal
    Loan Programs
    Mobile Service
    Morris County Chamber
    Neighbors Helping Neighbors
    News
    NJEDA
    Nonprofit
    Pharma
    Printers
    Pro Bono
    Retail
    Tourism
    Training
    Unemployment

    RSS Feed

Picture
JOIN Us   |   CONTACT Us  |  LEARN About Membership  |  REGISTER for Events  |  FIND a Member Business  |  READ our Magazines  |  LEAD Morris |  FAQ

Picture
325 Columbia Turnpike, ​​Suite 101
Florham Park, NJ 07932 

​973.539.3882 | CONTACT US | ​MAP
STAY CONNECTED: ​SIGN UP FOR UPDATES!
The Power of Connection!  Your membership connects you to valuable resources, opportunities for business growth and rewarding relationships with fellow members. And you don't need to be based in Morris County to belong!  
Our Office Hours are Monday to Friday, 9 am to 5 pm.  If you plan to stop by, it's best to make an appointment to ensure that someone will be available for you; the staff is often out of the office hosting events or meeting with members.
Follow  Us! 
The Morris County Economic Development Alliance (The Alliance) is an affiliated 501c3 Nonprofit of the Morris County Chamber and includes the Morris County Tourism Bureau, the Morris County Economic Development Corporation and the Connect To Morris job board.

©2025 Morris County Chamber of Commerce  |  A 501(c)(6) nonprofit membership organization  |  Site Map
  • JOIN
    • Become a Member
    • Premier Membership
    • What Members Are Saying >
      • Share a Testimonial
    • Membership Inquiry
    • The Value of Membership >
      • Grow Your Business
      • Build Your Brand
      • Professional Development & Education
      • Government Advocacy
      • Community Outreach & Volunteering
    • New Member Survey
    • Power of Connection
  • About
    • Chamber Team
    • Our Mission
    • Our President
    • Board of Directors
    • Morris Business Cabinet
    • President's Circle
    • Chamber Champions
    • Ambassadors Council
    • Inclusivity Advisory Council
    • Frequently Asked Questions
    • Code of Conduct & COVID Policy
  • Membership
    • Member Benefits
    • Forums & Committees >
      • Committee Chair Application
      • Business Development Forum
      • Business Strategy Forum
      • Health & Wellness Forum
      • Not For Profit Roundtable
      • Real Estate Forum
      • RISE Morris: Young Professionals Forum
      • Women in Business Program >
        • WIB Event Committee
    • Member to Member Deals
    • Member Marketing Opportunities
    • Grand Opening Support
    • Conference Room Usage
    • Member Referral Bonus
    • Connect to Morris Job Bank
  • Events
    • Chamber Event Calendar
    • Member Events Calendar
    • Signature Events & Programs
    • Golf Donations 2025
    • Event Photos
    • Submit an Event Idea
    • CCM Grant-Supported Training
  • Directory
    • Searchable Business Directory
    • Nonprofit Giving Guide 2024
    • Member Spotlights
    • Enhance Your Directory Listing
  • News & Info
    • Electronic Certificate of Origin
    • Business Resources & Info
    • Chamber Magazines
    • News Around the Chamber >
      • Around the Chamber Archive
      • Submit a Press Release
    • MCCC Blog >
      • Contribute to Our Blog
    • Members' Bookshelf >
      • Members Library Submission
  • Programs
    • Economic Development Corp
    • EDC Business Counseling
    • Public Policy Series
    • CEO Round Table
    • Lead Morris >
      • Lead Morris Program
      • Lead Morris Alumni Council
      • LEAD Morris Alumni Directory
      • Lead Morris FAQs
      • Lead Morris Application
      • LEAD Morris News & Info
      • Share a LEAD Morris Testimonial
    • Women In Business >
      • Women in Business Mastermind
      • Women in Business Executive Round Table
      • Women in Golf Program
    • Entrepreneur Roundtable
    • Thrive Morris >
      • Thrive Morris Community Leaders
      • Thrive Morris Blog
      • Contribute to the Thrive Morris Blog
  • Member Portal